microangiopathy

[‚mī·krō‚an·jē′äp·ə·thē]

(medicine)

The development of lesions in small blood vessels throughout the body.

References in periodicals archive ?

Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy

Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy

PON1 decreases lipid peroxide accumulation in LDL due to its antioxidant ability against hydroperoxides thus reduce LDL and phospholipid oxidation, Thus, PON1 may be involved against atherosclerosis protection.1 Diabetes mellitus (DM), is a life-threatening chronic disease associated with about 10% death episodes in adults.2 DM is leading risk factor for development of coronary heart diseases and mortality if not properly managed.3 In recent meta-analysis study that involved 35 studies worldwide, PON1 has been shown to decrease in DM and to be associated with the risk of diabetic macroangiopathy and microangiopathy.4 In addition, in another meta-analysis, PON1 polymorphisms have been shown to play an important role in the susceptibility of diabetic macroangiopathy and microangiopathy.5

Correlation of Paraoxonase-1 with glycated hemoglobin and lipid profile among Sudanese diabetic patients

Akari Therapeutics PLC (NASDAQ: AKTX) said the FDA has granted orphan drug designation for its namocopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Namocopan also has Fast Track designation for the same indication in pediatric patients.

The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

Food and Drug Administration has granted Fast Track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy in pediatric patients.

Akari Therapeutics receives FDA Fast Track Designation for nomacopan

Omeros is preparing to submit a biologics license application and a marketing authorization application to the US Food and Drug Administration and to the European Medicines Agency, respectively, for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).

Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab

The dermatologic diagnosis with the highest 30-day same-cause readmission rate was vascular hamartomas at 21.1%, followed by dermatomyositis (18.3%) and thrombotic microangiopathy (13.7%).

By the numbers: Readmissions for skin conditions

The product is intended to treat people with aHUS, a disease of the red blood cells, and inhibition of complement-mediated thrombotic microangiopathy. It is said to be the first and only long-acting C5 inhibitor administered every eight weeks and it works by inhibiting the C5 protein in the terminal complement cascade.

Alexion Pharmaceuticals' supplemental biologics licence application for Ultomiris priority review approved by US FDA

No evidence of thrombotic microangiopathy was present.

Sunitinib-Induced Acute Interstitial Nephritis in a Thrombocytopenic Renal Cell Cancer Patient

NEW YORK, N.Y., March 13, 2019 -- Akari Therapeutics, Plc (AKTX) announced that it completed a successful Type B, pre-IND meeting with the FDA regarding a proposed clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

FDA Approves Trial Of Treatment In Stem Cell Transplant-Related Condition

The alveolar-capillary network in the lung is a large microvascular unit and may be affected by microangiopathy. [3] The major morbidities in type 2 diabetes are due to its microangiopathic and macroangiopathic complications.

A study on pulmonary function parameters in type 2 diabetes mellitus

The involvement of kidney vessels is called renal microangiopathy and it plays an important role in diabetic nephropathy.

Diabetes, Oxidative Stress and Endothelial Dysfunction

No cases of thrombotic microangiopathy (TMA) or thrombotic events occurred.

United States : Genentechs Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors